EUVIMEDEUVIMED entdecken
Crossref

Clinicopathological Significance of HER2 Expression Redefined by the HER2-low Concept in Ductal Carcinoma In Situ

Koji Takada, Shinichiro Kashiwagi, Mayuko Hirata, Mariko Nishikawa, Chika Watanabe, Yukie Tauchi, Kana Ogisawa, Masatsune Shibutani, Haruhito Kinoshita, Tamami Morisaki

Anticancer Research · 2026

DOI: 10.21873/anticanres.17997 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2026. Verfasst von Koji Takada und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Carcinoma, Intraductal, Noninfiltrating, Breast Neoplasms.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: The introduction of the HER2-low concept has redefined the biological spectrum of breast cancer. However, the clinicopathological and prognostic significance of HER2 expression in ductal carcinoma in situ (DCIS) remains unclear. This study aimed to reassess HER2 expression in DCIS using the HER2-low classification. PATIENTS AND METHODS: A total of 221 patients who underwent surgery and were pathologically diagnosed with DCIS at Osaka Metropolitan University hospital between June 2007 and December 2023 were retrospectively analyzed. HER2 expression was assessed using immunohistochemistry (IHC) and classified as HER2-0, HER2-low (IHC 1-2+), or HER2-high (IHC 3+). Clinicopathological features were compared among groups, and disease-free survival (DFS) and recurrence-free interval (RFI) were evaluated using Kaplan-Meier and Cox regression analyses. RESULTS: HER2-0, HER2-low, and HER2-high were observed in 96 (43.4%), 80 (36.2%), and 45 (20.4%) patients, respectively. HER2 expression correlated significantly with estrogen receptor (p=0.011), progesterone receptor (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesCarcinoma, Intraductal, NoninfiltratingBreast NeoplasmsHumansFemalePrognosisMiddle AgedRetrospective StudiesBiomarkers, TumorAgedImmunohistochemistryDisease-Free SurvivalAdult

Stichwörter der Autor:innen

Ductal carcinoma in situHER2 expressionHER2-lowbreast cancerimmunohistochemistry

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
  • Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan; kashiwa@omu.ac.jp.
  • Department of Gastroenterological Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.

Zitieren

APA

Takada, K., Kashiwagi, S., Hirata, M., Nishikawa, M., Watanabe, C., Tauchi, Y., Ogisawa, K., Shibutani, M., Kinoshita, H., & Morisaki, T. (2026). Clinicopathological Significance of HER2 Expression Redefined by the HER2-low Concept in Ductal Carcinoma In Situ. Anticancer Research. https://doi.org/10.21873/anticanres.17997

Vancouver

Takada K, Kashiwagi S, Hirata M, Nishikawa M, Watanabe C, Tauchi Y, et al. Clinicopathological Significance of HER2 Expression Redefined by the HER2-low Concept in Ductal Carcinoma In Situ. Anticancer Research. 2026. doi:10.21873/anticanres.17997

BibTeX
@article{Takada2026,
  author = {Takada, Koji and Kashiwagi, Shinichiro and Hirata, Mayuko and Nishikawa, Mariko and Watanabe, Chika and Tauchi, Yukie and Ogisawa, Kana and Shibutani, Masatsune and Kinoshita, Haruhito and Morisaki, Tamami},
  title = {Clinicopathological Significance of HER2 Expression Redefined by the HER2-low Concept in Ductal Carcinoma In Situ},
  journal = {Anticancer Research},
  year = {2026},
  doi = {10.21873/anticanres.17997}
}
Kostenlos starten →